Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial

H E Bays, J L Evans, K C Maki, M Evans, V Maquet, R Cooper, J W Anderson, H E Bays, J L Evans, K C Maki, M Evans, V Maquet, R Cooper, J W Anderson

Abstract

Background/objectives: Elevated oxidized low-density lipoprotein (OxLDL) may promote inflammation, and is associated with increased risk of atherosclerotic coronary heart disease and worsening complications of diabetes mellitus. The primary objective of this study was to evaluate the efficacy of chitin-glucan (CG), alone and in combination with a potentially anti-inflammatory olive oil (OO) extract, for reducing OxLDL in subjects with borderline to high LDL cholesterol (LDL-C) levels.

Subjects/methods: This 6-week, randomized, double-blind, placebo-controlled study of a novel, insoluble fiber derived from the Aspergillus niger mycelium, CG, evaluated 130 subjects free of diabetes mellitus with fasting LDL-C 3.37-4.92 mmol/l and glucose ≤ 6.94 mmol/l. Participants were randomly assigned to receive CG (4.5 g/day; n=33), CG (1.5 g/day; n=32), CG (1.5 g/day) plus OO extract (135 mg/day; n=30), or matching placebo (n=35).

Results: Administration of 4.5 g/day CG for 6 weeks significantly reduced OxLDL compared with placebo (P=0.035). At the end of study, CG was associated with lower LDL-C levels relative to placebo, although this difference was statistically significant only for the CG 1.5 g/day group (P=0.019). CG did not significantly affect high-density lipoprotein cholesterol, triglycerides, glucose, insulin or F2-isoprostane levels. Adverse events did not substantively differ between treatments and placebo.

Conclusions: In this 6-week study, CG (4.5 g/day) reduced OxLDL, an effect that might affect the risk for atherosclerosis.

Trial registration: ClinicalTrials.gov NCT01232309.

Figures

Figure 1
Figure 1
Consolidated Standards for Reporting of Trials diagram. ITT, intent-to-treat; MITT, modified intent-to-treat. Refer to text for details. The dates for the initiation of recruitment through the completion of trial were September 2010 through January 2011, respectively.

References

    1. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
    1. Steinberg D, Witztum J. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:2311–2316.
    1. Mori K, Kobayashi C, Tomita T, Inatomi S, Ikeda M. Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa (Maitake), and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E-deficient mice. Nutr Res. 2008;28:335–342.
    1. Sun JE, Ao ZH, Lu ZM, Xu HY, Zhang XM, Dou WF, et al. Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of Inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. J Ethnopharmacol. 2008;118:7–13.
    1. Anderson JW, Baird P, Davis RH, Ferreri S, Knudtson M, Koraym A, et al. Health benefits of dietary fiber. Nutr Rev. 2009;67:188–205.
    1. Van HL, McCoin M, Kris-Etherton PM, Burke F, Carson JA, Champagne CM, et al. The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc. 2008;108:287–331.
    1. Nicolosi R, Bell SJ, Bistrian BR, Greenberg I, Forse RA, Blackburn GL. Plasma lipid changes after supplementation with beta-glucan fiber from yeast. Am J Clin Nutr. 1999;70:208–212.
    1. EFSA Panel on Dietetic Products NaAN Scientific Opinion on the substantiation of health claims related to beta glucans and maintenance of normal blood cholesterol concentrations (ID 754, 755, 757, 801, 1465, 2934) and maintenance or achievement of a normal body weight (ID 820, 823) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2009;7:1254.
    1. Berecochea-Lopez A, Decorde K, Ventura E, Godard M, Bornet A, Teissedre PL, et al. Fungal chitin-glucan from Aspergillus niger efficiently reduces aortic fatty streak accumulation in the high-fat fed hamster, an animal model of nutritionally induced atherosclerosis. J Agric Food Chem. 2009;57:1093–1098.
    1. Neyrinck A, Possemiers S, Verstraete W, De Backer F, Cani P, Delzenne N. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J Nutr Biochem. 2012;23:51–59.
    1. Deschamps A, Nollevaux G, Gautier S, Keller F. Managing oxidative stress with a vegetal ingredient, chitin-glucan. AgroFood. 2009;20:12–14.
    1. Covas MI, Nyyssonen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006;145:333–341.
    1. Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145:1–11.
    1. Fito M, Guxens M, Corella D, Saez G, Estruch R, De la Torre R, et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med. 2007;167:1195–1203.
    1. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. Nutr Rev. 2006;64 (2 Part 2:S27–S47.
    1. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ. 2008;337:a1344.
    1. Covas MI, Konstantinidou V, Fito M. Olive oil and cardiovascular health. J Cardiovasc Pharmacol. 2009;54:477–482.
    1. Ortega RM. Importance of functional foods in the Mediterranean diet. Public Health Nutr. 2006;9:1136–1140.
    1. Perez-Jimenez F, Alvarez de CG, Badimon L, Barja G, Battino M, Blanco A, et al. International conference on the healthy effect of virgin olive oil. Eur J Clin Invest. 2005;35 (7:421–424.
    1. Perez-Jimenez F, Ruano J, Perez-Martinez P, Lopez-Segura F, Lopez-Miranda J. The influence of olive oil on human health: not a question of fat alone. Mol Nutr Food Res. 2007;51:1199–1208.
    1. Tripoli E, Giammanco M, Tabacchi G, Di MD, Giammanco S, La GM. The phenolic compounds of olive oil: structure, biological activity and beneficial effects on human health. Nutr Res Rev. 2005;18:98–112.
    1. Cicero AF, Nascetti S, Lopez-Sabater MC, Elosua R, Salonen JT, Nyyssonen K, et al. Changes in LDL fatty acid composition as a response to olive oil treatment are inversely related to lipid oxidative damage: the EUROLIVE study. J Am Coll Nutr. 2008;27:314–320.
    1. Covas MI, de la Torre K, Farre-Albaladejo M, Kaikkonen J, Fito M, Lopez-Sabater C, et al. Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic compounds in humans. Free Radic Biol Med. 2006;40:608–616.
    1. Covas MI. Bioactive effects of olive oil phenolic compounds in humans: reduction of heart disease factors and oxidative damage. Inflammopharmacology. 2008;16:216–218.
    1. Fito M, De la Torre R, Covas MI. Olive oil and oxidative stress. Mol Nutr Food Res. 2007;51:1215–1224.
    1. Gimeno E, Torre-Carbot K, Lanuela-Raventos RM, Castellote AI, Fito M, de la Torre R, et al. Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial. Br J Nutr. 2007;98:1243–1250.
    1. Marrugat J, Covas MI, Fito M, Schroder H, Miro-Casas E, Gimeno E, et al. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation—a randomized controlled trial. Eur J Nutr. 2004;43:140–147.
    1. Weinbrenner T, Fito M, De la Torre R, Saez GT, Rijken P, Tormos C, et al. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. J Nutr. 2004;134:2314–2321.
    1. Glantz S.Primer of Biostatistics6th edn. (McGraw-Hill Medical: New York; 2005
    1. Azar RR, Badaoui G, Sarkis A, Azar M, Aydanian H, Harb S, et al. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Am J Cardiol. 2010;106:193–197.
    1. Holvoet P, Theilmeier G, Shivalkar B, Flameng W, Collen D. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. Arterioscler Thromb Vasc Biol. 1998;18:415–422.
    1. Bays HE. Adiposopathy: is sick fat a cardiovascular disease. J Am Coll Cardiol. 2011;57:2461–2473.
    1. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–944.
    1. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004;109:843–848.
    1. Biorklund M, van RA, Mensink RP, Onning G. Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: a randomised dose-controlled trial. Eur J Clin Nutr. 2005;59:1272–1281.
    1. Makelainen H, Anttila H, Sihvonen J, Hietanen RM, Tahvonen R, Salminen E, et al. The effect of beta-glucan on the glycemic and insulin index. Eur J Clin Nutr. 2007;61:779–785.
    1. Maki KC, Galant R, Samuel P, Tesser J, Witchger MS, Ribaya-Mercado JD, et al. Effects of consuming foods containing oat b-glucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. Eur J Clin Nutr. 2007;61:786–795.
    1. Maki KC, Rains TM.Fiber and insulin sensitivityIn: Zimering MB, edTopics in the Prevention, Treatment and Complications of Type 2 Diabetes InTech: New York; 2011177–190.Available at .
    1. Maki KC, Pelkman CL, Kelley KM, Lawless AL, Schild A, Rains TM. Effects of type 2 resistant starch consumption on insulin sensitivity in men and women. FASEB J. 2011;25:587.9.
    1. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995;155:381–386.
    1. Vissers MN, Zock PL, Katan MB. Bioavailability and antioxidant effects of olive oil phenols in humans: a review. Eur J Clin Nutr. 2004;58:955–965.
    1. Jonker D, Kuper CF, Maquet V, Nollevaux G, Gautier S. Subchronic (13-week) oral toxicity study in rats with fungal chitin-glucan from Aspergillus niger. Food Chem Toxicol. 2010;48:2695–2701.
    1. Soni MG, Burdock GA, Christian MS, Bitler CM, Crea R. Safety assessment of aqueous olive pulp extract as an antioxidant or antimicrobial agent in foods. Food Chem Toxicol. 2006;44:903–915.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever